Literature DB >> 28475811

Ablation of Hepatic Production of the Acid-Labile Subunit in Bovine-GH Transgenic Mice: Effects on Organ and Skeletal Growth.

Zhongbo Liu1, Tianzhen Han1, Shannon Fishman2, James Butler2, Tracy Zimmermann2, Frederic Tremblay2, Carole Harbison2, Nidhi Agrawal3, John J Kopchick4,5, Mitchell B Schaffler6, Shoshana Yakar1.   

Abstract

Growth hormone (GH) and insulinlike growth factor 1 (IGF-1) are anabolic hormones that facilitate somatic and skeletal growth and regulate metabolism via endocrine and autocrine/paracrine mechanisms. We hypothesized that excess tissue production of GH would protect skeletal growth and integrity in states of reduction in serum IGF-1 levels. To test our hypothesis, we used bovine GH (bGH) transgenic mice as a model of GH hypersecretion and ablated the liver-derived acid-labile subunit, which stabilizes IGF-1 complexes with IGF-binding protein-3 and -5 in circulation. We used a genetic approach to create bGH/als gene knockout (ALSKO) mice and small interfering RNA (siRNA) gene-silencing approach to reduce als or igf-1 gene expression. We found that in both models, decreased IGF-1 levels in serum were associated with decreased body and skeletal size of the bGH mice. Excess GH produced more robust bones but compromised mechanical properties in male mice. Excess GH production in tissues did not protect from trabecular bone loss in response to reductions in serum IGF-1 (in bGH/ALSKO or bGH mice treated with siRNAs). Reduced serum IGF-1 levels in the bGH mice did not alleviate the hyperinsulinemia and did not resolve liver or kidney pathologies that resulted from GH hypersecretion. We concluded that reduced serum IGF-1 levels decrease somatic and skeletal growth even in states of excess GH.
Copyright © 2017 Endocrine Society.

Entities:  

Mesh:

Substances:

Year:  2017        PMID: 28475811      PMCID: PMC5551555          DOI: 10.1210/en.2016-1952

Source DB:  PubMed          Journal:  Endocrinology        ISSN: 0013-7227            Impact factor:   4.736


  50 in total

Review 1.  The acid-labile subunit (ALS) of the 150 kDa IGF-binding protein complex: an important but forgotten component of the circulating IGF system.

Authors:  Y R Boisclair; R P Rhoads; I Ueki; J Wang; G T Ooi
Journal:  J Endocrinol       Date:  2001-07       Impact factor: 4.286

Review 2.  Acid-labile subunit deficiency: phenotypic similarities and differences between human and mouse.

Authors:  H M Domené; S V Bengolea; H G Jasper; Y R Boisclair
Journal:  J Endocrinol Invest       Date:  2005       Impact factor: 4.256

3.  Bone mineral density and turnover in patients with acromegaly in relation to sex, disease activity, and gonadal function.

Authors:  Marek Bolanowski; Jacek Daroszewski; Marek Medraś; Beata Zadrozna-Sliwka
Journal:  J Bone Miner Metab       Date:  2006       Impact factor: 2.626

4.  Organization and regulation of the gene encoding the sheep acid-labile subunit of the 150-kilodalton insulin-like growth factor-binding protein complex.

Authors:  R P Rhoads; P L Greenwood; A W Bell; Y R Boisclair
Journal:  Endocrinology       Date:  2000-04       Impact factor: 4.736

Review 5.  Transgenic models of growth hormone action.

Authors:  J J Kopchick; L L Bellush; K T Coschigano
Journal:  Annu Rev Nutr       Date:  1999       Impact factor: 11.848

6.  Circulating levels of IGF-1 directly regulate bone growth and density.

Authors:  Shoshana Yakar; Clifford J Rosen; Wesley G Beamer; Cheryl L Ackert-Bicknell; Yiping Wu; Jun-Li Liu; Guck T Ooi; Jennifer Setser; Jan Frystyk; Yves R Boisclair; Derek LeRoith
Journal:  J Clin Invest       Date:  2002-09       Impact factor: 14.808

7.  Serum IGF-1 is insufficient to restore skeletal size in the total absence of the growth hormone receptor.

Authors:  Yingjie Wu; Hui Sun; Jelena Basta-Pljakic; Luis Cardoso; Oran D Kennedy; Hector Jasper; Horacio Domené; Liliana Karabatas; Clara Guida; Mitchell B Schaffler; Clifford J Rosen; Shoshana Yakar
Journal:  J Bone Miner Res       Date:  2013-07       Impact factor: 6.741

Review 8.  Spectrum of insulin-like growth factor deficiency.

Authors:  Jan M Wit; W Oostdijk; M Losekoot
Journal:  Endocr Dev       Date:  2012-11-23

9.  ERRγ is not required for skeletal development but is a RUNX2-dependent negative regulator of postnatal bone formation in male mice.

Authors:  Marco Cardelli; Jane E Aubin
Journal:  PLoS One       Date:  2014-10-14       Impact factor: 3.240

10.  Growth Hormone Control of Hepatic Lipid Metabolism.

Authors:  Zhongbo Liu; Jose Cordoba-Chacon; Rhonda D Kineman; Bruce N Cronstein; Radhika Muzumdar; Zhenwei Gong; Haim Werner; Shoshana Yakar
Journal:  Diabetes       Date:  2016-09-27       Impact factor: 9.461

View more
  4 in total

1.  Mitochondrial Function Is Compromised in Cortical Bone Osteocytes of Long-Lived Growth Hormone Receptor Null Mice.

Authors:  Zhongbo Liu; Maria E Solesio; Mitchell B Schaffler; Dorra Frikha-Benayed; Clifford J Rosen; Haim Werner; John J Kopchick; Evgeny V Pavlov; Andrey Y Abramov; Shoshana Yakar
Journal:  J Bone Miner Res       Date:  2018-09-14       Impact factor: 6.741

2.  Ablation of Growth Hormone Receptor in GABAergic Neurons Leads to Increased Pulsatile Growth Hormone Secretion.

Authors:  Willian O Dos Santos; Frederick Wasinski; Mariana R Tavares; Ana M P Campos; Carol F Elias; Edward O List; John J Kopchick; Raphael E Szawka; Jose Donato
Journal:  Endocrinology       Date:  2022-08-01       Impact factor: 5.051

3.  Insulin-Like Growth Factors-1 Receptor (IGF-1R) Expression and the Phosphorylation of Endogenous Substrates Lead to Maturation of the Pacific oyster, Crassostrea gigas.

Authors:  Su-Jin Park; Youn Hee Choi
Journal:  Dev Reprod       Date:  2021-03-31

4.  GH directly inhibits steatosis and liver injury in a sex-dependent and IGF1-independent manner.

Authors:  Andre Sarmento-Cabral; Mercedes Del Rio-Moreno; Mari C Vazquez-Borrego; Mariyah Mahmood; Elena Gutierrez-Casado; Natalie Pelke; Grace Guzman; Papasani V Subbaiah; Jose Cordoba-Chacon; Shoshana Yakar; Rhonda D Kineman
Journal:  J Endocrinol       Date:  2021-01       Impact factor: 4.286

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.